This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06926842 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Zealand Pharma |
| Enrollment | 221 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Overweight; Type 2 Diabetes; Obesity |
| Interventions | Petrelintide; Placebo |
| Start | Apr 22, 2025 |
| Primary completion | Aug 13, 2026 |
| Study completion | Aug 13, 2026 |
| Results posted | Not yet |
| Registry last updated | Sep 9, 2026 |
| Collaborators | Parexel |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percentage Change in Body Weight | From Baseline (Day 1) to Weeks 28 |
15 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 30, 2026. See the trial changes feed for what has changed recently.
More trials of Petrelintide
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
